We're On A Path To Deliver!

CSE: PHRM   |   OTCQB: PHRRF

Press Releases

PharmaTher Expands to Neuromuscular Diseases with Exclusive License Agreement for Ketamine in the Treatment of Lou Gehrig’s Disease

March 02, 2021

Newscope Announces DTC Eligibility of Its Common Shares in the United States

​

March 01, 2021

PharmaTher Announces Research Collaboration with Terasaki Institute for Novel Microneedle Delivery of Psychedelic Pharmaceuticals

February 23, 2021

PharmaTher Announces Sale of Psilocybin Program

​

February 17, 2021

PharmaTher Announces Successful Completion of Pre-IND Meeting with FDA for the Clinical Development of Ketamine in the Treatment of Parkinson’s Disease

February 04, 2021

PharmaTher Signs Exclusive Worldwide License Agreement for Patented Microneedle Delivery Technology to Deliver Ketamine
​

February 01, 2021

Register For Our Latest Developments
​And Events

Connect With Us

PharmaTher Inc.
82 Richmond Street East
Toronto, Ontario  Canada
M5C 1P1